Cargando...
4CPS-069 Economic impact of off-label use of dalbavancin for treatment of infectious endocarditis and bloodstream infections caused by grampositive bacteria
BACKGROUND: Dalbavancin (DBV) is an antibiotic from the lipoglycopeptide family that is active against Gram +cocci (GPC) that reaches adequate concentrations to allow dosing once a week. It is currently only approved for skin and soft tissue infections, although its PK/PD properties could allow a po...
Guardado en:
| Publicado en: | Eur J Hosp Pharm |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BMJ Group
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535182/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.160 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|